Sagimet Biosciences (SGMT) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

SGMT Sagimet Biosciences

Watchlist

5.190
+0.880+20.42%

Close Oct 14 16:00 ET

5.260
+0.070+1.35%

Pre 09:12 ET

167.09MMarket Cap-5659P/E (TTM)

Pre-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Sector Update: Health Care Stocks Edge Higher Pre-Bell Friday
MT NewswiresOct 11 09:24 ET
Sagimet Biosciences' MASH Drug Meets Main, Secondary Goals in Phase 2b Study
MT NewswiresOct 11 07:41 ET
Express News | Sagimet Biosciences Inc - Denifanstat Shows Significant Improvements in Mash Resolution and Fibrosis
ReutersOct 11 07:00 ET
Sagimet Biosciences Announces Publication of Results From Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
GlobeNewswireOct 11 07:00 ET
Express News | Sagimet Biosciences Announces Publication of Results From Phase 2B Fascinate-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 Mash in the Lancet Gastroenterology & Hepatology
ReutersOct 11 07:00 ET
Sagimet Biosciences' Denifanstat Receives Buy Rating on FDA's BTD and Promising Trial Results
TipRanksOct 4 02:39 ET · Ratings

Comments

Jaguar8

Oct 11 06:04

NEWS

$Sagimet Biosciences (SGMT.US)$
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...

Trytosaveabit

Oct 1 14:21

$Sagimet Biosciences (SGMT.US)$ Nice to see a bit of a recovery🤫

Rivera

Oct 1 07:50

Nice

$Sagimet Biosciences (SGMT.US)$

Jaguar8

Oct 1 06:09

NEWS

$Sagimet Biosciences (SGMT.US)$
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...